FDA setback for Sanofi’s Tolebrutinib in progressive MS
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
Adverse events were consistent with valbenazine’s established safety profile
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Subscribe To Our Newsletter & Stay Updated